Candel presents preclinical data at SITC for enLIGHTEN platform; Alpha-201-macro1 shows enhanced cancer cell killing

Candel Therapeutics, Inc.

Preclinical data for enLIGHTEN Discovery Platform presented at SITC 2023 Annual Meeting in San Diego.
Alpha-201-macro1, first experimental agent from platform, targets CD47/SIRPα pathway via local delivery.
enLIGHTEN Advanced Analytics suite predicted multi-gene payload combinations from ICI-treated patient datasets.
Viral chassis Alpha-201 armed with immunostimulatory payloads enhanced PBMC-mediated cancer cell killing in preclinical models.
Data validate in silico prediction of payload combinations using human datasets to de-risk viral immunotherapy development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.